Advertisement

Topics

Companies Related to "Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)" [Most Relevant Company Matches] RSS

10:39 EDT 21st October 2018 | BioPortfolio

Here are the most relevant search results for "Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)" found in our extensive corporate database of over 50,000 company records.

Showing "Efficacy Safety Mepolizumab Treatment Chronic Obstructive Pulmonary Disease" Companies 1–25 of 6,700+

Extremely Relevant

Uptake Medical Corp.

Uptake Medical(TM) Corp. is a developer of medical technologies for the treatment of lung diseases including emphysema. The core technology is a simple, minimally invasive, non-implant interventional pulmonary approach designed to measurably improve lung function and patient quality of life. Emphysema afflicts over 3 million people in the United States. It is a form of chronic obstructive pulmonar...


Pearl Therapeutics Inc.

Pearl Therapeutics is developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Leveraging its proprietary particle technology, formulation expertise and unparalleled product development experience, Pearl is rapidly advancing a pipeline of products that offer patients and healthcare professionals ...

Synspira

Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and pneumonia. Synspira has an exclusive license from Synedgen to the Glycomics Technology Platform fo...


COPD Foundation

Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the U.S. and the only chronic disease growing in mortality. It affects approximately 24 million Americans but only 12 million are diagnosed. COPD includes chronic bronchitis, emphysema, and adult onset (refractory) asthma. Symptoms include breathlessness, wheezing, and chr...

Spiros Development Corporation

Spiros Development Corporation develops the Spiros-Registered Trademark-, a dry powder pulmonary drug delivery system, and to conduct formulation work, clinical trials and commercialization for certain specified leading asthma and chronic obstructive pulmonary disease ("COPD") drugs for use with Spiros.

Pharmaxis Ltd

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is launched in a number of key markets. Its development pipeline of products includes: Bronchitol for cystic fibrosis, b...

ResMed Inc.

ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-m...

The COPD Foundation

The mission of the COPD Foundation is to develop and support programs, which improve the quality of life through research, education, early diagnosis and enhanced therapy for persons whose lives are impacted by Chronic Obstructive Pulmonary Disease.

MicroDose Therapeutx, Inc.

MicroDose Therapeutx is a privately-held pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases. The company focuses on developing proprietary products that address large unmet market opportunities, and on drug delivery platforms for the pulmonary, oral, and transdermal delivery of medications. The comp...

Freedom Health, Inc. and Optimum Healthcare, Inc.

Headquartered in Tampa, FL, Freedom Health, Inc. and Optimum Healthcare Inc. provide comprehensive health care coverage through their Medicare Advantage Plans in the state of Florida. The health plans offer multiple benefit options including MAPD, Dual Special Needs Plans covering individuals with both Medicare and Medicaid eligibility and Chronic Special ...

Cureveda LLC

Cureveda LLC was co-founded in 2010 by Johns Hopkins Bloomberg School of Public Health faculty members Shyam Biswal and Rajesh Thimmulappa together with Christy Wyskiel. The company is focused on the discovery, development and commercialization of drugs for the treatment of inflammatory, autoimmune and neurogenerative diseases. Cureveda is developing Nrf2 ...

EPIX Pharmaceuticals

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, ...

Somnus Medical Technology

Somnus Medical Technologies was formed to address several large, underserved opportunities in the management of the upper airway. The company currently markets Somnoplasty® as a treatment for obstructive sleep apnea arising from obstruction at the base of the tongue, habitual snoring from enlarged soft palate and uvula and chronic nasal obstruction caused by the turbinates. Obstructive sleep apne...

Relevant

Almirall Ltd

Almirall, an international pharmaceutical company is based on innovation and committed to health. Headquartered in Barcelona, Spain, the company researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing. The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma...

Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company’s lead therapy, HI-164OV is based on the Company’s proprietary technology that uses the application of mucosal immunology to treat common human diseases.  HI-164OV, in Phase IIb clinica...

Rotech Healthcare Inc.

Rotech Healthcare Inc. is one of the largest providers of home medical equipment and related products and services in the United States, with a comprehensive offering of respiratory therapy and durable home medical equipment and related services. The Company provides home medical equipment and related products and services principally to older patients wit...

Fibrotech Therapeutics

Fibrotech is an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis (tissue scarring). The Company develops novel anti-fibrotic drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as chronic kidney disease, chronic heart failure, pulmonary fibros...

Duska Therapeutics, Inc.

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for t...

SeniorBridge

SeniorBridge, founded in 2000 and with offices throughout the United States, is a provider of care management. The company addresses the total well-being of clients and their families through a comprehensive program that includes assessment, planning, service coordination, advocacy and direct care by a multidisciplinary team led by a professional geriatric...

Vivonoetics Inc.

Vivonoetics Inc., founded in 2009, and based in San Diego, CA, is a leader in body-worn technology for clinical research. Through the use of Vivonoetics core laboratory services and VivoSense® technology, pharmaceutical researchers can obtain high quality data solutions describing a patient's physiological status in ambulatory and home settings. Vivonoe...

MicroDose Technologies, Inc.

MicroDose Technologies, Inc. is a privately held premier drug delivery and specialty pharmaceuticals company. Founded in 1998, MicroDose is pioneering the use of proprietary drug delivery platforms for the pulmonary, oral and transdermal delivery of medications for improved efficacy and compliance. MicroDose's current focus is on the chronic disease states such as asthma, COPD, diabetes, hypertens...

Ario Pharma Ltd

ario pharma ltd focusses on the development of drugs for the treatment of respiratory indications. Ario is about to evaluate the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials that will read out in 2014. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease. Co...

Entest BioMedical Inc.

Entest BioMedical Inc. (OTC Bulletin Board: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTC Bulletin Board: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The C...

Pulmonary Hypertension Association

Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual. The function of the heart and lungs is severely compromised, manifested by a limited exercise capacity, and, ultimately, a reduced life expectancy. Approximately 100,000 people in Europe and the United S...

Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects “Paradoxical Pharmacologyâ...


More From BioPortfolio on "Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks